Why the study?
Does an ELISA-based collagen binding assay (CBA) improve the diagnosis and differentiation of Type I and Type II von Willebrand's disease compared to standard assays?
Population
Plasma samples from patients with Type I von Willebrand's disease, Type II von Willebrand's disease…
Comparison
ELISA-based collagen binding assay (CBA) vs Standard von Willebrand factor antigen ELISA and…
Design
Other
Authors
Loading...
May aid differentiation of Type II from Type I vWD; leaves open routine adoption pending prospective validation.
Does an ELISA-based collagen binding assay (CBA) improve the diagnosis and differentiation of Type I and Type II von Willebrand's disease compared to standard assays?
The newly developed ELISA-based collagen binding assay effectively differentiates Type II from Type I von Willebrand's disease by detecting qualitative vWF differences.
Favaloro et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: